Long-term proliferating early pre B cell lines and clones with the potential to develop to surface Ig-positive, mitogen reactive B cells in vitro and in vivo - PubMed (original) (raw)

Long-term proliferating early pre B cell lines and clones with the potential to develop to surface Ig-positive, mitogen reactive B cells in vitro and in vivo

A Rolink et al. EMBO J. 1991 Feb.

Abstract

Cell lines and clones were established from PB76-positive mouse fetal liver at day 13 and 14 of gestation, which proliferated with division times of a day in serum-substituted cultures under the stimulatory influence of adherent stromal cells and the cytokine IL-7 for periods longer than half a year. These lines expressed varying levels of the B lymphocyte lineage related markers PB76, B220, BP-1, VpreB and lambda 5, but no surface Ig or MHC class II molecules. All clones expressed PB76, VpreB and lambda 5 in a high percentage of cells, while B220 and/or BP-1 expression was low or undetectable in some. A cell line, and several clones established from it, all had kappa and lambda light chain genes in germ-line configuration. Either one or both of their H-chain-gene containing chromosomes carried a DH to JH. These pre B cell lines and clones could be induced to VH to DH and VL to JL rearrangements. This resulted in the development of varying percentages of sIg-positive surface, MHC class II negative, LPS-reactive B cells within 2-3 days, in the absence of contacts with stromal cells and/or IL-7. When injected into SCID mice, the cultured pre B cells populated the spleen of these mice to 5% with surface Ig-, MHC class II-positive LPS-reactive cells for greater than 25 weeks. The long-term in vitro proliferative capacity of these DH-JH rearranged pre B cell clones makes them major candidates for committed stem cells of the B lineage.

PubMed Disclaimer

Cited by

Division of labor within the DNA damage tolerance system reveals non-epistatic and clinically actionable targets for precision cancer medicine.
Spanjaard A, Shah R, de Groot D, Buoninfante OA, Morris B, Lieftink C, Pritchard C, Zürcher LM, Ormel S, Catsman JJI, de Korte-Grimmerink R, Siteur B, Proost N, Boadum T, van de Ven M, Song JY, Kreft M, van den Berk PCM, Beijersbergen RL, Jacobs H. Spanjaard A, et al. Nucleic Acids Res. 2022 Jul 22;50(13):7420-7435. doi: 10.1093/nar/gkac545. Nucleic Acids Res. 2022. PMID: 35819193 Free PMC article.
Forward and Reverse Genetics of B Cell Malignancies: From Insertional Mutagenesis to CRISPR-Cas.
Dawes JC, Uren AG. Dawes JC, et al. Front Immunol. 2021 Aug 13;12:670280. doi: 10.3389/fimmu.2021.670280. eCollection 2021. Front Immunol. 2021. PMID: 34484175 Free PMC article. Review.
RAG-Mediated DNA Breaks Attenuate PU.1 Activity in Early B Cells through Activation of a SPIC-BCLAF1 Complex.
Soodgupta D, White LS, Yang W, Johnston R, Andrews JM, Kohyama M, Murphy KM, Mosammaparast N, Payton JE, Bednarski JJ. Soodgupta D, et al. Cell Rep. 2019 Oct 22;29(4):829-843.e5. doi: 10.1016/j.celrep.2019.09.026. Cell Rep. 2019. PMID: 31644907 Free PMC article.
At the intersection of DNA damage and immune responses.
Bednarski JJ, Sleckman BP. Bednarski JJ, et al. Nat Rev Immunol. 2019 Apr;19(4):231-242. doi: 10.1038/s41577-019-0135-6. Nat Rev Immunol. 2019. PMID: 30778174 Free PMC article. Review.
Editorial: Making Science Fun - A Tribute to Our Colleague and Friend, Prof. Antonius G. Rolink (1953-2017).
Eibel H, Winkler T, Ceredig R. Eibel H, et al. Front Immunol. 2018 Dec 19;9:2915. doi: 10.3389/fimmu.2018.02915. eCollection 2018. Front Immunol. 2018. PMID: 30619279 Free PMC article. No abstract available.

References

1. Eur J Immunol. 1972 Aug;2(4):349-53 - PubMed
1. J Cell Physiol. 1984 Mar;118(3):233-40 - PubMed
1. J Exp Med. 1977 Jun 1;145(6):1511-9 - PubMed
1. Eur J Immunol. 1977 Jul;7(7):476-81 - PubMed
1. Eur J Immunol. 1989 Feb;19(2):347-56 - PubMed

Long-term proliferating early pre B cell lines and clones with the potential to develop to surface Ig-positive, mitogen reactive B cells in vitro and in vivo - PubMed (original) (raw)